Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The epidermal growth factor receptor antagonists market was valued at USD 15.50 Billion in 2025 and is expected to grow at a CAGR of 9.13%, reaching USD 37.13 Billion by 2035. The market growth is driven by rising cancer prevalence, expanding applications in targeted therapy, and ongoing clinical trials for new indications.
-
As EGFR antagonists provide better outcomes with fewer side effects than traditional treatments, they are being increasingly preferred as a targeted cancer therapy. This is boosting the growth of the market.
-
The United States is anticipated to dominate the market due to its well-developed infrastructure, and several ventures in oncology investigation.
-
One of the major market trends includes the development of next generation EGFR antagonists for offering personalised treatment alternatives to patients.
Compound Annual Growth Rate
9.13%
Value in USD Billion
2026-2035
Epidermal Growth Factor Receptor Antagonists Market Overview
Epidermal growth factor receptor (EGFR) antagonists are medications that hinder the function of EGFR, a protein located on the surface of cells. If EGFR malfunctions, it can cause cancer cells to multiply and divide more rapidly. EGFR inhibitors are utilized in the management of cancer types such as lung, colorectal, and head and neck cancers. These drugs function by inhibiting the growth and metastasis of cancer cells, playing a vital role in modern cancer treatment.
Epidermal Growth Factor Receptor Antagonists Market Growth Drivers
Increasing Prevalence of Cancer
The growing prevalence of cancer cases worldwide is a key driver behind the growth of the market. According to the World Health Organization (WHO), in 2022, approximately 20 million new cancer cases were reported, along with 9.7 million deaths. Roughly 1 out of every 5 people will experience a cancer diagnosis during their lives. Additionally, around 1 in 9 men and 1 in 12 women are likely to die from cancer, thereby propelling the demand for effective treatments.
Technological Advancements Drives Market Growth
Another significant factor driving the growth of the market includes advancements in targeted cancer medicines. As medical research advances, more effective and precise EGFR antagonists are being discovered, aimed at producing better results with fewer adverse effects than standard chemotherapy, boosting their use in cancer treatment.
Epidermal Growth Factor Receptor Antagonists Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Doctors are increasingly using a combination of EGFR antagonists, along with other cancer treatments such as immunotherapy and chemotherapy to combat cancer symptoms and related ailments. This method focuses on enhancing patient results by combating the cancer from various perspectives. There is a high probability that this trend will persist as additional studies validate the advantages of combination treatments.
Personalised medicine is becoming more popular, as therapies are customized to each patient's genetic composition. The prevalence of EGFR testing is increasing, enabling doctors to administer antagonists to patients who are expected to gain the most from them. With the progression of personalized medicine, this tendency is expected to have a greater impact on cancer care in the forecast period.
Scientists are developing advanced EGFR antagonists to address resistance in initial therapies. These recently developed medications target tumors that have developed a resistance to existing EGFR inhibitors. For instance, in April 2023, Boston-based biotech company Scorpion Therapeutics revealed a collaboration with Pierre Fabre from France to jointly work on two advanced EGFR inhibitors, STX-241 and STX-721, designed for mutations in lung cancer. Initially, Scorpion received USD 65 million for the development of STX-721, with Pierre Fabre managing STX-241. As these medications are introduced, they are expected to impact the treatment of EGFR-related cancers.
Pharmaceutical companies are venturing into developing markets such as Asia-Pacific and Latin America. Access to advanced cancer treatments, such as EGFR antagonists, is increasing as healthcare infrastructure improves in these areas. Anticipated growth will persist due to the growing demand for cancer therapies in these areas.
Epidermal Growth Factor Receptor Antagonists Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug
- Cetuximab
- Erlotinib
- Gefitinib
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
Market Breakup by Application
- Lung Cancer
- Liver Cancer
- Breast Cancer
- Others
Market Breakup by End User
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Homecare Settings
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Epidermal Growth Factor Receptor Antagonists Market Share
Oral Segment is Anticipated to Witness Substantial Growth in Route of Administration Section
Based on the route of administration, the market is divided into oral and parenteral. Among these, the oral route is projected to dominate the market due to its accessibility for patients. Oral EGFR antagonists allow patients to take their medication at home instead of visiting the hospital frequently, thereby, making treatment more manageable. This is especially relevant for long-term medicines like cancer treatment when patient comfort and convenience are essential. As a result, the demand for oral EGFR antagonists has increased dramatically, influencing the present market scenario.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Epidermal Growth Factor Receptor Antagonists Market by Region
Based on regional segmentation, the market is categorized into the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. Among these, the United States holds the largest market share because of factors including a high percentage of healthcare spending, advanced healthcare systems, and a high level of investment in research and development. This dominance affects the present market situation in various ways, affecting global treatment protocols, clinical research, and the incorporation of new therapeutic regimes. As the attractive opportunities increase, more pharmaceutical companies are opting to invest in the U.S. market to meet these healthcare needs and enhance patients' quality of life.
Leading Players in the Epidermal Growth Factor Receptor Antagonists Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Johnson & Johnson Inc.
It was founded in 1886 and is based in New Brunswick, New Jersey. The company works on cancer medicines, including EGFR antagonists such as Amivantamab. Johnson & Johnson specializes in advanced lung cancer medicines and is committed to oncology innovation.
Eli Lilly and Company
Eli Lilly, a well-known pharmaceutical company, was founded in 1876 and is headquartered in Indianapolis, Indiana. Its pharmaceutical line includes Portrazza (necitumumab), an EGFR antagonist intended to treat squamous non-small cell lung cancer (NSCLC).
AstraZeneca
AstraZeneca was founded in 1999 and has its headquarters in Cambridge, United Kingdom. It is a cancer therapy market leader, notably with Tagrisso, a popular EGFR antagonist. AstraZeneca's priority remains developing next-generation EGFR inhibitors and increasing their usage in various phases of lung cancer therapy.
Pfizer, Inc.
Pfizer, a major pharmaceutical corporation established in 1849, is based in New York, USA. Their product portfolio includes Iressa (gefitinib), which is an EGFR inhibitor utilized to treat non-small cell lung cancer. Pfizer continues to invest extensively in oncology research, hoping to enhance cancer treatment outcomes worldwide.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies include TAIHO Pharma, F-Hoffmann La Roche Ltd., Lutris Pharma, Boehringer Ingelheim Pharmaceuticals, Inc., DAIICHI SANKYO COMPANY, LIMITED, and HUTCHMED.
Key Questions Answered in the Epidermal Growth Factor Receptor Antagonists Market
- What was the epidermal growth factor receptor antagonists market value in 2025?
- What is the epidermal growth factor receptor antagonists market forecast outlook for 2026-2035?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on the drug class?
- What is the market breakup based on the route of administration?
- What is the market segmentation based on the application?
- What is the market breakup based on the end user?
- What is the market segmentation based on the distribution channel?
- What major factors aid the epidermal growth factor receptor antagonists market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major epidermal growth factor receptor antagonists market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players in the epidermal growth factor receptor antagonists market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
- What factors drive the adoption of targeted therapies in hospitals and clinics?
- How is the rise of online pharmacies affecting the distribution of targeted therapies?
- How does the United States lead in the market for targeted cancer therapies?
Pricing Plans
Upto 15% Off
USD
-
$3299 $2969
-
$5499 $4949
-
$6999 $5949
-
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drugs |
|
| Breakup by Route of Administration |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
